What is RNTX's change in deferred revenue?

RNTX (RNTX) reported change in deferred revenue of -$178K in Q4 2025.

How has RNTX's change in deferred revenue changed year-over-year?

RNTX's change in deferred revenue increased by 54.2% year-over-year, from -$388.5K to -$178K.

Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.

4D Molecular TherapeuticsFDMT

$1.38M+9,957%

Revenue-—

Operating income-$5.2M+6.8%

Net income-$5.8M-6.1%

EPS (diluted)-$0.19+24.0%

Cash & equivalents$4.4M-40.2%

Total debt$48.0K0.0%

Total equity$6.9M-63.0%

Total assets$26.3M-54.4%

Operating cash flow-$3.4M+44.6%

CapEx-—

Free cash flow-$6.3M—

Market cap$88.96M+164%

Return on equity-123.3%+86.1pp

Debt / equity0×0.0×

Current ratio0.4×-1.0×

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredLiabilities.

The official record: RNTX’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is RNTX's change in deferred revenue?: RNTX (RNTX) reported change in deferred revenue of -$178K in Q4 2025.
How has RNTX's change in deferred revenue changed year-over-year?: RNTX's change in deferred revenue increased by 54.2% year-over-year, from -$388.5K to -$178K.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.